State Board of Administration of Florida Retirement System raised its position in Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) by 16.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 22,729 shares of the company’s stock after buying an additional 3,129 shares during the period. State Board of Administration of Florida Retirement System owned about 0.06% of Zeltiq Aesthetics worth $621,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Legal & General Group Plc boosted its position in Zeltiq Aesthetics by 1.7% in the first quarter. Legal & General Group Plc now owns 4,963 shares of the company’s stock worth $134,000 after buying an additional 83 shares in the last quarter. Calamos Wealth Management LLC acquired a new position in Zeltiq Aesthetics during the second quarter worth approximately $200,000. BNP Paribas Arbitrage SA boosted its position in Zeltiq Aesthetics by 119.1% in the second quarter. BNP Paribas Arbitrage SA now owns 10,262 shares of the company’s stock worth $280,000 after buying an additional 5,579 shares in the last quarter. Quantbot Technologies LP acquired a new position in Zeltiq Aesthetics during the second quarter worth approximately $289,000. Finally, M&T Bank Corp acquired a new position in Zeltiq Aesthetics during the first quarter worth approximately $294,000.
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) traded down 1.76% during trading on Monday, reaching $38.53. The company had a trading volume of 377,950 shares. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of 57.94 and a beta of 0.79. The company’s 50-day moving average is $38.40 and its 200 day moving average is $31.34. Zeltiq Aesthetics Inc. has a 52 week low of $18.41 and a 52 week high of $40.98.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its earnings results on Monday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.07. The firm earned $89.50 million during the quarter, compared to analysts’ expectations of $79.68 million. Zeltiq Aesthetics had a net margin of 9.54% and a negative return on equity of 9.90%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 EPS. Equities analysts anticipate that Zeltiq Aesthetics Inc. will post ($0.13) EPS for the current year.
A number of research firms have issued reports on ZLTQ. Zacks Investment Research downgraded Zeltiq Aesthetics from a “hold” rating to a “sell” rating in a research note on Thursday, July 14th. TheStreet downgraded Zeltiq Aesthetics from a “buy” rating to a “hold” rating in a research note on Friday, June 10th. Leerink Swann reaffirmed an “outperform” rating and issued a $48.00 price objective on shares of Zeltiq Aesthetics in a research note on Thursday, August 25th. Brean Capital set a $39.00 price objective on Zeltiq Aesthetics and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $35.00 price objective (up previously from $27.00) on shares of Zeltiq Aesthetics in a research note on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $39.89.
In other news, VP Bradley Hauser sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $30.02, for a total value of $90,060.00. Following the transaction, the vice president now owns 47,184 shares in the company, valued at $1,416,463.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kevin C. Oboyle sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $40.08, for a total value of $300,600.00. Following the completion of the transaction, the director now owns 19,485 shares in the company, valued at approximately $780,958.80. The disclosure for this sale can be found here. 15.60% of the stock is owned by insiders.
Zeltiq Aesthetics Company Profile
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Want to see what other hedge funds are holding ZLTQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ).
Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.